For these reasons, the current updated guidelines also state that, given the growing knowledge on cancer-drivers involved in the development, progression, and therapy-resistance of NSCLC as well as the increase of molecularly targeted drugs, it is appropriate to include BRAF, KRAS, MET, ERBB2, RET, NTRK as part of larger multiplexed NGS testing panels performed either initially or when routine EGFR, ALK, and ROS1 testing are negative [49,50]. This evidence concerns the gene MET and cancer.